Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Psoriasis, Psoriatic Arthritis
Interventions: Intermittent Fasting Diet; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Psoriasis Vulgaris
Interventions: Secukinumab; Drug
Lead sponsor: Narrows Institute for Biomedical Research; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Psoriasis
Interventions: Mindfulness-Based Stress Reduction, Living Well; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Chronic Plaque-type Psoriasis
Interventions: AIN457, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: San Diego, California • Louisville, Kentucky • Rochester, New York + 2 more

Conditions: Scalp Psoriasis
Interventions: Calcipotriene and betamethasone suspension, Taclonex, Placebo; Drug
Lead sponsor: Tolmar Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 34
States / cities: Hot Springs, Arkansas • Fremont, California • Los Angeles, California + 28 more

Conditions: Scalp Psoriasis
Interventions: Betamethasone Scalp Suspension 0.064%;0.0005%, Taclonex®, Placebo topical suspension; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Psoriasis
Interventions: Otezla; Drug
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Autoimmune Diseases, Systemic Inflammatory Process, Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis
Interventions: Fish Oil, Vitamin D, placebo pill; Drug · Dietary Supplement · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older
Enrollment: 25,871 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis, Psoriasis
Interventions: Phone calls, Desoximetasone 0.25% spray; Behavioral · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Psoriasis
Interventions: LY3462817 - IV, LY3462817 - SC, Placebo - IV, Placebo - SC, LY3509754, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 10
States / cities: Los Angeles, California • Miami, Florida • Tampa, Florida + 4 more

Conditions: Joint Diseases, Osteoarthritis, Hip, Rheumatoid Arthritis, Psoriatic Arthritis, Avascular Necrosis of Hip
Interventions: Routine Total Hip Arthroplasty; Device
Lead sponsor: Ortho Development Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Psoriasis
Interventions: Recombinant human interleukin-10; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Plaque-type Psoriasis
Interventions: AIN457, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 25
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 21 more

Conditions: Psoriasis, Inflammation
Interventions: Methotrexate, Ustekinumab, Etanercept, Adalimumab, Acitretin, UVB Excimer Laser, Narrowband UVB; Drug · Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Psoriasis, Psoriasis Vulgaris, Psoriasis Universalis, Psoriasis Face, Psoriasis Nail, Psoriatic Plaque, Psoriasis Diffusa, Psoriasis Punctata, Psoriasis Palmaris, Psoriasis Circinata, Psoriasis Annularis, Psoriasis Genital, Psoriasis of Scalp, Psoriasis Geographica
Interventions: No Intervention; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Plaque Psoriasis, Psoriasis
Interventions: Cetaphil; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Columbus, Georgia • Douglasville, Georgia • High Point, North Carolina

Conditions: Palmoplantar Pustulosis (PPP)
Interventions: Spesolimab, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Birmingham, Alabama • Beverly Hills, California • San Diego, California + 11 more

Conditions: Psoriatic Arthritis
Interventions: Tofacitinib 5 mg BID, Tofacitinib 10 mg BID, Adalimumab, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 24
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 17 more

Conditions: Generalized Pustular Psoriasis
Interventions: Not listed
Lead sponsor: CorEvitas; Network
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases, Rheumatic Joint Disease, PsA (Psoriatic Arthritis), AxSpA, Rheumatologic Disease
Interventions: SPY002-072, Placebo; Drug
Lead sponsor: Spyre Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Avondale, Arizona • Tucson, Arizona • Chula Vista, California + 14 more

Conditions: Chronic Plaque Psoriasis
Interventions: Belumosudil, Placebo; Drug
Lead sponsor: Kadmon Corporation, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 14
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 11 more

Conditions: Healthy Volunteer, Psoriasis
Interventions: ABBV-547, ABBV-547 Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Bryant, Arkansas • Anaheim, California + 15 more

Conditions: Plaque Psoriasis, Skin Diseases, Papulosquamous, Skin Diseases
Interventions: AM001 Cream, 7.5%, Placebo of AM001 Cream; Drug
Lead sponsor: AmDerma; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Miami, Florida • Fridley, Minnesota • Albuquerque, New Mexico + 2 more

Conditions: Plaque Psoriasis
Interventions: Clobex Spray; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Fort Gratiot, Michigan

Search by objective public record fields.

Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis

Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).

Improving Psoriasis Through Health and Well-Being

A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis

Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain

Evaluating Treatment Resistant Dermatitis TaroIIR

A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

Survivorship and Patient Outcomes of Primary Total Hip Arthroplasty With the Ovation Hip System

Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis

AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis

Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients

A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

A Study of SPY072 in Rheumatic Disease

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%